QT Vascular downplays competitor’s patent claim

It will not affect the group’s profitability.

QT Vascular today reiterated its stance that the patent infringement claim filed against the company will not have a material effect on its financial position or profitability.

Its challenger, specialty balloon angioplasty company AngioScore, alleged that QT Vascular’s Chocolate PTA infringes the ‘119 Patent, a patent that claims a very specific design for an angioplasty balloon catheter and a non-deployable stent.

QT Vascular today stated that there is a “minimal” probability that AngioScore could obtain a permanent injunction against the Chocolate PTA because AngioScore does not practice the ’119 Patent

The group further stated that a new available design of Chocolate PTA will materially reduce the risks related to the patent claim on Chocolate PTA.

QT Vascular noted that the patent claim does not implicate intellectual property and the Group is not at risk of losing intellectual property including patent applications as a consequence of the claim.

Also Read

Singaporeans' physical well-being at highest level since 2019

SingHealth partners with OutcomesAI to integrate AI into medical workflows

Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!

I want to download the media kit